188 related articles for article (PubMed ID: 23587424)
1. Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
Polepally PR; White K; Vardy E; Roth BL; Ferreira D; Zjawiony JK
Bioorg Med Chem Lett; 2013 May; 23(10):2860-2. PubMed ID: 23587424
[TBL] [Abstract][Full Text] [Related]
2. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL
J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611
[TBL] [Abstract][Full Text] [Related]
3. New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.
Lee DY; Ma Z; Liu-Chen LY; Wang Y; Chen Y; Carlezon WA; Cohen B
Bioorg Med Chem; 2005 Oct; 13(19):5635-9. PubMed ID: 16084728
[TBL] [Abstract][Full Text] [Related]
4. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.
Cruz A; Domingos S; Gallardo E; Martinho A
Phytochemistry; 2017 May; 137():9-14. PubMed ID: 28190678
[TBL] [Abstract][Full Text] [Related]
5. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
6. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M
Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370
[TBL] [Abstract][Full Text] [Related]
7. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
Simpson DS; Katavic PL; Lozama A; Harding WW; Parrish D; Deschamps JR; Dersch CM; Partilla JS; Rothman RB; Navarro H; Prisinzano TE
J Med Chem; 2007 Jul; 50(15):3596-603. PubMed ID: 17580847
[TBL] [Abstract][Full Text] [Related]
8. A review of salvinorin analogs and their kappa-opioid receptor activity.
Roach JJ; Shenvi RA
Bioorg Med Chem Lett; 2018 May; 28(9):1436-1445. PubMed ID: 29615341
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.
Riley AP; Groer CE; Young D; Ewald AW; Kivell BM; Prisinzano TE
J Med Chem; 2014 Dec; 57(24):10464-75. PubMed ID: 25426797
[TBL] [Abstract][Full Text] [Related]
10. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.
Cunningham CW; Rothman RB; Prisinzano TE
Pharmacol Rev; 2011 Jun; 63(2):316-47. PubMed ID: 21444610
[TBL] [Abstract][Full Text] [Related]
11. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
Harding WW; Schmidt M; Tidgewell K; Kannan P; Holden KG; Gilmour B; Navarro H; Rothman RB; Prisinzano TE
J Nat Prod; 2006 Jan; 69(1):107-12. PubMed ID: 16441078
[TBL] [Abstract][Full Text] [Related]
12. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.
Munro TA; Rizzacasa MA; Roth BL; Toth BA; Yan F
J Med Chem; 2005 Jan; 48(2):345-8. PubMed ID: 15658846
[TBL] [Abstract][Full Text] [Related]
13. Isolation and chemical modification of clerodane diterpenoids from Salvia species as potential agonists at the kappa-opioid receptor.
Li Y; Husbands SM; Mahon MF; Traynor JR; Rowan MG
Chem Biodivers; 2007 Jul; 4(7):1586-93. PubMed ID: 17638340
[TBL] [Abstract][Full Text] [Related]
14. Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.
Polepally PR; Huben K; Vardy E; Setola V; Mosier PD; Roth BL; Zjawiony JK
Eur J Med Chem; 2014 Oct; 85():818-29. PubMed ID: 25193297
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.
Capasso R; Borrelli F; Cascio MG; Aviello G; Huben K; Zjawiony JK; Marini P; Romano B; Di Marzo V; Capasso F; Izzo AA
Br J Pharmacol; 2008 Nov; 155(5):681-9. PubMed ID: 18622408
[TBL] [Abstract][Full Text] [Related]
16. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
[TBL] [Abstract][Full Text] [Related]
17. [Salvinorin A and related diterpenes--biological activity and potential therapeutic uses].
Piekielna J; Fichna J; Janecka A
Postepy Biochem; 2012; 58(4):485-91. PubMed ID: 23662442
[TBL] [Abstract][Full Text] [Related]
18. Chemical syntheses of the salvinorin chemotype of KOR agonist.
Hill SJ; Brion AUCM; Shenvi RA
Nat Prod Rep; 2020 Nov; 37(11):1478-1496. PubMed ID: 32808003
[TBL] [Abstract][Full Text] [Related]
19. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.
Butelman ER; Harris TJ; Kreek MJ
Psychopharmacology (Berl); 2004 Mar; 172(2):220-4. PubMed ID: 14586540
[TBL] [Abstract][Full Text] [Related]
20. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.
Fichna J; Schicho R; Janecka A; Zjawiony JK; Storr M
Drug News Perspect; 2009 Sep; 22(7):383-92. PubMed ID: 19890495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
